1Warm congratulations Recently, Parr Bio’s independently developed world’s first influenza vaccine containing CpG adjuvant (Project Code: HP-3001) has been approved by the National Medical Products Administration (NMPA). As an
🎉Event: The 53rd Annual Meeting of the Japanese Society of Toxicology (JSOT 2026) 📅Date: July 1 (Wed) – July 3 (Fri), 2026 📍 Venue: Osaka International Convention Center,
About KAL · Deep Expertise Setting an Industry Benchmark JIANGSU KAL BIOTECH INC. (“KAL Biotech”) is a nationally certified enterprise specializing in the standardized breeding and supply of
🎉Event: BIO-EUROPE SPRING 2026 📅Date: 23–25 March 2026 📍 Venue: Feira Internacional de Lisboa, Pavilion 2, Lisbon, Portugal 💁 KCI‘s Booth: #34 About KCI KCI Biotech and its wholly-owned subsidiaries
On October 28, 2024, Ms. Li, the R&D director of Chunhai Biotechnology, came to KCI BioTech and presented us with a bright banner. On
Recently, KAL Biotech Inc. (hereinafter referred to as “KAL Biotech”), a wholly-owned subsidiary of KCI Biotech Inc, successfully obtained the “Experimental Animal Production License” officially issued
“One has only to believe that you can – and you are already halfway to the goal.”
Ullamcorper tellus non nam quis purus lacus, magna purus.
Comprehensive preclinical drug development and service platform
Building A2, No, 8 Yanghua road, Suzhou industrial Park, Suzhou.P.R, china
